Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
AmMax Bio, clinical stage targeted oncology ADC company, names biopharmaceutical Executive Travis Read as President and COO.
-
– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial – – 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML – ...
-
EVX-04 is successfully expressed and secreted in human cells enabling immune recognition and activationThe vaccine antigens drive specific immune responses across different human immune profiles and...
-
InnoCare's novel BCL2i mesutoclax in MDS and AML was released at 2026 ASCO as an oral presentation, demonstrating outstanding efficacy and safety.
-
– 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg once-daily dose – – Central MRD negativity in 75% of CRc responders with...
-
The data show that mesutoclax demonstrates outstanding efficacy and safety in treating various hematologic malignancies.
-
Entries are now open for the inaugural Future Digital Awards for Identity & Security 2026. Apply via the entry form on the website. Entry is free.
-
AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- SEON, the AI Command Center for Fraud Prevention and AML Compliance, today announced the appointment of Sagnik Nandy, Chief Technology Officer and...
-
TOKYO and SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) and Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) today announced the first patient has been...
-
Exicure enters co-development agreement with Adbiotech to advance Burixafor (GPC-100) combination therapies across multiple indications.